Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 3
2013 6
2014 3
2015 1
2016 5
2017 11
2018 6
2019 7
2020 4
2021 6
2022 7
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Bevacizumab in recurrent WHO grades II-III glioma.
Annakib S, Rigau V, Darlix A, Gozé C, Duffau H, Bauchet L, Jarlier M, Fabbro M. Annakib S, et al. Among authors: jarlier m. Front Oncol. 2023 Jul 18;13:1212714. doi: 10.3389/fonc.2023.1212714. eCollection 2023. Front Oncol. 2023. PMID: 37534252 Free PMC article.
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer.
Rabia E, Garambois V, Dhommée C, Larbouret C, Lajoie L, Buscail Y, Jimenez-Dominguez G, Choblet-Thery S, Liaudet-Coopman E, Cerutti M, Jarlier M, Ravel P, Gros L, Pirot N, Thibault G, Zhukovsky EA, Gérard PE, Pèlegrin A, Colinge J, Chardès T. Rabia E, et al. Among authors: jarlier m. Front Immunol. 2023 Apr 20;14:1168444. doi: 10.3389/fimmu.2023.1168444. eCollection 2023. Front Immunol. 2023. PMID: 37153618 Free PMC article.
Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells.
Cherradi S, Garambois V, Marines J, Andrade AF, Fauvre A, Morand O, Fargal M, Mancouri F, Ayrolles-Torro A, Vezzo-Vié N, Jarlier M, Loussaint G, Huvelle S, Joubert N, Mazard T, Gongora C, Pourquier P, Boissière-Michot F, Rio MD. Cherradi S, et al. Among authors: jarlier m. Cell Biosci. 2023 Apr 11;13(1):72. doi: 10.1186/s13578-023-01015-5. Cell Biosci. 2023. PMID: 37041570 Free PMC article.
A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer.
Grosgeorges M, Picque Lasorsa L, Pastor B, Prévostel C, Crapez E, Sanchez C, Frayssinoux F, Jarlier M, Pezzella V, Monard L, Ychou M, Thierry AR, Mazard T, Blache P. Grosgeorges M, et al. Among authors: jarlier m. Sci Rep. 2023 Feb 15;13(1):2739. doi: 10.1038/s41598-023-29948-4. Sci Rep. 2023. PMID: 36792801 Free PMC article.
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Desroys du Roure P, Lajoie L, Mallavialle A, Alcaraz LB, Mansouri H, Fenou L, Garambois V, Rubio L, David T, Coenon L, Boissière-Michot F, Chateau MC, Ngo G, Jarlier M, Villalba M, Martineau P, Laurent-Matha V, Roger P, Guiu S, Chardès T, Gros L, Liaudet-Coopman E. Desroys du Roure P, et al. Among authors: jarlier m. J Immunother Cancer. 2024 Jan 30;12(1):e007135. doi: 10.1136/jitc-2023-007135. J Immunother Cancer. 2024. PMID: 38290768 Free PMC article.
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models.
Rabia E, Garambois V, Hubert J, Bruciamacchie M, Pirot N, Delpech H, Broyon M, Theillet C, Colombo PE, Vie N, Tosi D, Gongora C, Khellaf L, Jarlier M, Radosevic-Robin N, Chardès T, Pèlegrin A, Larbouret C. Rabia E, et al. Among authors: jarlier m. MAbs. 2021 Jan-Dec;13(1):1914883. doi: 10.1080/19420862.2021.1914883. MAbs. 2021. PMID: 33876707 Free PMC article.
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz LB, Roger P, Guiu S, Derocq D, Robin G, Michaud HA, Delpech H, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Simony-Lafontaine J, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget JP, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E. Ashraf Y, et al. Among authors: jarlier m. J Immunother Cancer. 2019 Feb 4;7(1):29. doi: 10.1186/s40425-019-0498-z. J Immunother Cancer. 2019. PMID: 30717773 Free PMC article.
65 results